This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Embolism Stroke Strokes 
Open Heart
JANUARY 31, 2025
Life-threatening complications of infective endocarditis (IE,) are heart failure, uncontrolled infection and embolic events (EE), which pose significant morbidity and mortality risks. Depending on the location and severity of the embolism, the embolic risk can either escalate or alternatively, complicate and delay cardiac surgery.
52 
CardiacWire
JANUARY 24, 2025
Fully published results from Athos Therapeutics AZALEA-TIMI 71 trial for its novel Factor XI inhibitor abelacimab, confirming the drugs lower bleeding risks, but leaving researchers uncertain about its ability to prevent stroke in AFib patients. vs. 0.4%) and 4X ischemic stroke rates (csHR = 4.06). year follow-up. per 100 person-year.
59 
CardiacWire
FEBRUARY 12, 2025
Bayer terminated its OCEANIC-AF trial for its Factor XI inhibitor, asundexian, due to 3x greater stroke (1.3% vs. 0.4%) and 4x higher ischemic stroke rates (csHR = 4.06). Results from BMS AXIOMATIC-SSP study found that its Factor XI inhibitor, milvexian, failed to meaningfully reduce ischemic stroke.
102 
HeartRhythm
MARCH 14, 2024
Artificial intelligence (AI)-enabled sinus rhythm (SR) electrocardiogram (ECG) interpretation can aid in identifying undiagnosed paroxysmal atrial fibrillation (AF) in patients with embolic stroke of undetermined source (ESUS).
Frontiers in Cardiovascular Medicine
MARCH 3, 2024
Background Covert atrial fibrillation (AF) is a predominant aetiology of embolic stroke of undetermined source (ESUS). Evidence suggested that AF is more frequently detected by implantable loop recorder (ILR) than by conventional monitoring.
Med Page Today
JUNE 5, 2024
(MedPage Today) -- NEW YORK CITY -- Researchers eked out evidence of a small clinical benefit with the Sentinel cerebral embolic protection (CEP) device in transcatheter aortic valve replacement (TAVR) -- and pointed to the patients more likely.
105 
Nature Reviews - Cardiology
APRIL 9, 2025
Nature Reviews Cardiology, Published online: 10 April 2025; doi:10.1038/s41569-025-01156-9 Findings from the BHF PROTECT-TAVI trial indicate that the routine use of cerebral embolic protection devices during transcatheter aortic valve implantation does not decrease the incidence of stroke within 72 h after the intervention.
46 
Med Page Today
MARCH 30, 2025
(MedPage Today) -- CHICAGO -- Routine use of devices to prevent cerebral emboli during transcatheter aortic valve implantation (TAVI) did not prevent strokes, a large randomized trial showed. Incidence of stroke within 72 hours after TAVI or.
52 
Frontiers in Cardiovascular Medicine
APRIL 3, 2025
BackgroundNon-valvular atrial fibrillation (NVAF) significantly increases ischemic stroke and systemic embolism (SE) risks. for stroke/SE-specific, p-value<0.001). Despite the proven efficacy of oral anticoagulants (OAC) in reducing these risks, their underutilization highlights a gap in clinical practice.
American College of Cardiology
MARCH 30, 2025
Use of a cerebral embolic protection (CEP) device did not decrease the incidence of stroke within 72 hours after participants underwent TAVI, according to new research presented during a Late-Breaking Clinical Trial session at ACC.25 25 in Chicago and simultaneously published in NEJM.
58 
Journal of Cardiothoracic Surgery
JUNE 26, 2024
Although rare, paradoxical embolism sometimes occurs with patent ductus arteriosus (PDA). This study presents a case of PDA-associated paradoxical embolism with acute ischemic stroke (AIS) and pulmonary emboli.
52 
HCPLive
MARCH 27, 2025
OAC-naive patients experienced a significantly smaller increase in stroke or systemic embolism with asundexian than apixaban.
52 
HeartRhythm
APRIL 30, 2024
AF detection rates with implantable cardiac monitoring (ICM) following cryptogenic stroke are >12% at 12 months. Similar results have been reported in some non-cryptogenic stroke cohorts. Real-world data has also shown a much lower rate of AF detection.
40 
Stroke Journal
JANUARY 30, 2025
Stroke, Volume 56, Issue Suppl_1 , Page ATP388-ATP388, February 1, 2025. Introduction:Embolic Stroke of Undetermined Source (ESUS) accounts for a critical proportion of all ischemic strokes. Disambiguating embolism etiology is important to improve treatment efficacy and reduce recurrent events.
40 
Heart BMJ
MAY 10, 2024
Objectives The use of cerebral embolic protection (CEP) during transcatheter aortic valve implantation (TAVI) has been studied in several randomised trials. We aimed to perform a systematic review and Bayesian meta-analysis of randomised CEP trials, focusing on a clinically relevant reduction in disabling stroke.
52 
HeartRhythm
APRIL 30, 2024
The association between AF detected by implanted cardiac implantable electronic devices (CIEDs) and the incidence of embolic stroke has been reported. Moreover, the cut-off value of new-onset AF duration detected by CIEDs for embolic stroke is still unknown.
HeartRhythm
APRIL 30, 2024
Atrial fibrillation (AF) has been known as a main cause of embolic stroke. Well-chosen candidate to be anticoagulated should be critical for secondary prevention in patients with embolic stroke with undetermined source (ESUS).
Frontiers in Cardiovascular Medicine
MAY 19, 2024
Although generally considered a benign anatomic variant, a PFO may facilitate passage of a thrombus from the venous to arterial circulation, thereby resulting in cryptogenic stroke or systemic embolization.
52 
Journal of Cardiothoracic Surgery
APRIL 7, 2024
Pulmonary embolism is the most common cardiovascular disease after myocardial infarction and stroke. Konstantinides (Eur Heart J 41(4):543–603, 2020) Current guidelines categorize patients with PE as being at.
52 
Frontiers in Cardiovascular Medicine
FEBRUARY 4, 2024
Anticoagulation is the mainstay of stroke prevention in appropriate patients with atrial fibrillation. An investigational class of agents which inhibit Factor XI have shown promise in pre-clinical and early clinical trials to significantly minimize bleeding while maintaining efficacy against stroke and systemic embolism.
The New England Journal of Medicine
MARCH 29, 2025
In a randomized trial, the routine use of cerebral embolic protection during TAVI did not reduce the incidence of stroke within 72 hours or before discharge from the hospital (if discharge occurred sooner).
40 Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page ATP259-ATP259, February 1, 2024. Background and Purpose:Right-to-left shunt (RLS) is one of the potential embolic sources in embolic stroke of undetermined source (ESUS), but the eligibility of conducting shunt study to detect RLS in ESUS is still unknown. cm/s, p = 0.021).
40 American College of Cardiology
OCTOBER 29, 2024
The goal of the PROTECTED TAVR trial was to evaluate the efficacy of intraprocedural cerebral embolic protection (CEP) in reducing strokes among patients undergoing transfemoral TAVR for aortic stenosis.
45 
Journal of the American Heart Association
NOVEMBER 28, 2023
BackgroundDisambiguation of embolus pathogenesis in embolic strokes is often a clinical challenge. One common source of embolic stroke is the carotid arteries, with emboli originating due to plaque buildup or perioperatively during revascularization procedures.
40 
Frontiers in Cardiovascular Medicine
APRIL 3, 2025
Except for 2 cases (1.4%) of micropericardial effusion, there were no other complications such as cardiac tamponade, major bleeding, stroke oroccluder embolization. The procedural success rate was 99.3%. During the 12-month follow-up, serious adverse events occurred in 3 patients (2.2%), all of which were device-related thrombus (DRT).
52 
All About Cardiovascular System and Disorders
FEBRUARY 19, 2024
In an earlier post on Embolic Stroke of Undetermined Source (ESUS) , I had mentioned about ARCADIA trial (AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke) which was testing whether there is role for apixaban compared to aspirin for prevention of recurrent stroke in ESUS. 2023.27188.
52 
Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page A42-A42, February 1, 2024. Introduction:A new Plaque-RADS classification (I-IV) is proposed to categorize the degree of carotid plaque instability and risk of embolic ischemic stroke. Carotid total plaque thickness and ulceration were scored by a neuroradiologist blinded to stroke side.
40 
Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page ATP223-ATP223, February 1, 2024. Background:A considerable portion of patients with embolic stroke of unknown source(ESUS)are later found to have occult atrial fibrillation (AF).
Stroke Journal
JANUARY 30, 2025
Stroke, Volume 56, Issue Suppl_1 , Page AWMP98-AWMP98, February 1, 2025. Background:The use of oral anticoagulation (OAC) for stroke prevention in embolic stroke of undetermined source (ESUS) is hypothesized to be beneficial over conventional antiplatelet use. A random-effects model was used for the analyses. RevMan Web).Results:14,582
40 
The New England Journal of Medicine
JANUARY 1, 2025
A randomized trial of the factor XIa inhibitor asundexian was stopped early owing to a higher incidence of stroke or systemic embolism than with apixaban therapy among patients with atrial fibrillation.
Journal of the American Heart Association
MARCH 21, 2025
Patients were stratified according to polygenic risk score tertiles and observed for the occurrence of ischemic stroke or systemic embolism, myocardial infarction, and heart failure hospitalization. P=0.011) for ischemic stroke or systemic embolism, 1.15 (95% CI, 0.821.61;P=0.422) During a median followup of 4.6
Journal of the American Heart Association
MARCH 21, 2025
BackgroundWe aimed to reevaluate randomized controlled trial data on outcomes of cerebral embolic protection device use during transcatheter aortic valve implantation. Primary outcomes included all stroke, disabling stroke, and allcause mortality.
40 
DAIC
JANUARY 24, 2025
This underuse of anticoagulants for stroke prevention has been cited as one of the greatest public health issues facing cardiovascular patients 6. Many doctors are put in the unfortunate position of having to weigh the risk of stroke against the risk of bleeding for their patients with AFib, said Christian T.
52 
American College of Cardiology
FEBRUARY 23, 2024
What is the incidence of the embolic and bleeding complications in relation to pre- and post- periprocedure antithrombotic regimens in patients undergoing ventricular arrhythmia radiofrequency ablation (RFA)?
65 
The British Journal of Cardiology
NOVEMBER 29, 2023
Stroke is a major cause of mortality, morbidity and economic burden. Strokes can be thrombotic, embolic or haemorrhagic. The key risk factor for cardioembolic stroke is atrial fibrillation or flutter, and oral anticoagulation (OAC) is recommended in all but the lowest-risk patients with evidence of these arrhythmias.
40 
Frontiers in Cardiovascular Medicine
JANUARY 11, 2024
Patent foramen ovale (PFO) is the most common congenital intracardiac defect that can cause right-to-left shunting and contribute to the paradoxical embolization of venous emboli, and even lead to stroke. We report the case of a young man who presented with cerebral infarction accompanied by both HES and PFO.
59 Stroke Journal
JANUARY 30, 2025
Stroke, Volume 56, Issue Suppl_1 , Page ATP324-ATP324, February 1, 2025. Background and Purpose:Antiphospholipid antibody syndrome (APS) is a rare cause of cerebral infarction, but the effect of antiphospholipid antibodies (aPL) on the acute phase of ischemic stroke in each stroke subtypes is still unclear, especially in the elderly patients.
40 
DAIC
MARCH 26, 2024
Addressing the serious issue of delayed and missed findings in diagnostic imaging, CINA-iPE is an AI-powered tool that detects incidental pulmonary embolism during routine CT scans. This is particularly relevant in the cancer patient population, where pulmonary embolism is a significant cause of mortality.
105 
ECG Cases
SEPTEMBER 12, 2023
The post ECG Cases 45 ECG in Weakness and Neurological Symptoms appeared first on Emergency Medicine Cases.
131 
Frontiers in Cardiovascular Medicine
DECEMBER 20, 2023
Massive pulmonary embolism (MPE) carries significant 30-day mortality and is characterized by acute right ventricular failure, hypotension, and hypoxia, leading to cardiovascular collapse and cardiac arrest. Considerable heterogeneity in studies is a significant weakness of the available literature.
56 HeartRhythm
APRIL 24, 2024
Abnormal conduction, structure and function of the atrial myocardium predispose to atrial fibrillation (AF) and stroke. Usefulness of electrocardiographic (ECG) indices in predicting stroke or systemic embolism (SSE) in patients undergoing cardioversion for AF remains unknown, especially in those at low estimated risk.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content